Reports Q2 revenue $4.47M vs $3.648M last year. “I am pleased to finish out another quarter with continued clinical execution, including positive data in Graves’ Disease and FDA’s clearance of INDs in 5 indications at Immunovant,” said Matt Gline, CEO of Roivant. “I am also excited today to present the 52-week data from our Phase 2 study of brepocitinib in NIU. The sustained treatment benefits observed further our belief that brepocitinib is a potentially compelling and durable agent for a disease that is poorly treated today. We have a busy year ahead with major data expected in 2025 from Immunovant and Priovant, along with continued execution across other programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ROIV:
- ROIV Earnings this Week: How Will it Perform?
- Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
- Organon completes acquisition of Dermavant
- JPMorgan SMid cap biotech analyst holds an analyst/industry conference call
- Eyes on Fed ahead of expected interest rate cut: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
